Sarah Bair, MD
Dermatopathology · Loveland, CONPI 1760670863
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,590 of the $2,062 with a category attached, or 77.1%. 17 manufacturers reported payments, led by Merz North America, Inc. at 47.9% of the total. Reporting peaked in 2022 at $1,159 and has fallen 92.6% since, to $86 in 2025.
Across 63 payments — averaging $32.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merz North America, Inc.$987
- Pfizer$169
- LEO Pharma Inc.$165
- Novartis$126
- AbbVie$117
- Galderma Laboratories, L.p.$105
- plus $393 from 11 others
What the payments were for
- Travel & lodging$47223%
- Food & beverage$1,59077%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merz North America, Inc. | 9 | $987 |
| Pfizer | 12 | $169 |
| LEO Pharma Inc. | 7 | $165 |
| Novartis | 7 | $126 |
| AbbVie | 2 | $117 |
| Galderma Laboratories, L.p. | 3 | $105 |
| Sanofi | 5 | $89 |
| Amgen | 5 | $75 |
| Sun Pharmaceutical Industries Inc. | 2 | $50 |
| Regeneron Healthcare Solutions, Inc. | 3 | $47 |
| Johnson & Johnson | 2 | $31 |
| Incyte Corporation | 1 | $20 |
| UCB, Inc. | 1 | $20 |
| Lilly USA, LLC | 1 | $18 |
| Journey Medical Corporation | 1 | $17 |
| VYNE Pharmaceuticals Inc. | 1 | $15 |
| Organon | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XEOMIN$630
How this compares
Too few dermatopathology providers in Coloradoto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fluorouracil | 150 | $10,423 |
| CiclopiroxCiclopirox Olamine | 353 | $8,598 |
| Clobetasol Propionate | 69 | $2,975 |
| Ketoconazole | 173 | $2,973 |
| Metronidazole | 33 | $2,036 |
| Triamcinolone Acetonide | 223 | $1,346 |
| Ciclopirox | 36 | $1,117 |
| Mupirocin | 73 | $529 |
| Clindamycin Phosphate | 26 | $465 |
| ValacyclovirValacyclovir Hcl | 23 | $241 |
| Doxycycline Hyclate | 17 | $168 |
Paid to pharmacies, not to this prescriber.
Other dermatopathology in Loveland
- Ingerlisa MattochLoveland$5K
- Narina GroveLoveland$48
- Aaron HooverGreeley$7K
- Sean AmsbaughAurora$4K
- Jean UrquhartEagle$744
- James HuffAurora$591
- Robert WrightDenver$229
- Sidney HoskinsDurango$205
- Whitney HighAurora$165
- Edward WrightRifle$136
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.